Trademark: 88639756
Word
VICDUR
Status
Dead
Status Code
606
Status Date
Monday, June 5, 2023
Serial Number
88639756
Mark Type
4000
Filing Date
Wednesday, October 2, 2019
Published for Opposition
Tuesday, March 10, 2020
Abandoned Date
Monday, June 5, 2023

Trademark Owner History

Classifications
5 Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), huntington's disease, lewy body dementia, frontotemporal dementia, vascular dementia, parkinson's disease, cognitive impairment of aging, progressive multiple sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in parkinson's disease, agitation in ad, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to nmda receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, post traumatic stress disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, obsessive compulsive disorder (OCD), hoarding, trichotillomania, eating disorders, generalized anxiety disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, attention deficit disorder (ADD), pervasive developmental disorders (PDD), asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use; all of the foregoing specifically excluding medicated and pharmaceutical preparations and substances for the treatment or management of respiratory diseases and disorders

Trademark Events
Jun 5, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Jun 5, 2023
Abandonment - No Use Statement Filed
Oct 28, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 28, 2022
Teas Change Of Correspondence Received
Oct 28, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 28, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 28, 2022
Teas Change Of Owner Address Received
Oct 4, 2022
Notice Of Approval Of Extension Request E-Mailed
Oct 3, 2022
Sou Extension 5 Granted
Sep 22, 2022
Sou Extension 5 Filed
Oct 3, 2022
Case Assigned To Intent To Use Paralegal
Sep 22, 2022
Teas Extension Received
Apr 28, 2022
Notice Of Approval Of Extension Request E-Mailed
Apr 26, 2022
Sou Extension 4 Granted
Apr 26, 2022
Sou Extension 4 Filed
Apr 26, 2022
Teas Extension Received
Oct 27, 2021
Notice Of Approval Of Extension Request E-Mailed
Oct 25, 2021
Sou Extension 3 Granted
Oct 25, 2021
Sou Extension 3 Filed
Oct 25, 2021
Teas Extension Received
Apr 30, 2021
Notice Of Approval Of Extension Request E-Mailed
Apr 28, 2021
Sou Extension 2 Granted
Apr 28, 2021
Sou Extension 2 Filed
Apr 28, 2021
Teas Extension Received
Oct 17, 2020
Notice Of Approval Of Extension Request E-Mailed
Oct 15, 2020
Sou Extension 1 Granted
Oct 15, 2020
Sou Extension 1 Filed
Oct 15, 2020
Teas Extension Received
May 5, 2020
Noa E-Mailed - Sou Required From Applicant
Mar 10, 2020
Official Gazette Publication Confirmation E-Mailed
Mar 10, 2020
Published For Opposition
Feb 19, 2020
Notification Of Notice Of Publication E-Mailed
Feb 6, 2020
Approved For Pub - Principal Register
Feb 3, 2020
Teas/Email Correspondence Entered
Jan 23, 2020
Correspondence Received In Law Office
Feb 3, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Jan 29, 2020
Assigned To Lie
Jan 23, 2020
Teas Response To Office Action Received
Jan 9, 2020
Notification Of Non-Final Action E-Mailed
Jan 9, 2020
Non-Final Action E-Mailed
Jan 9, 2020
Non-Final Action Written
Jan 7, 2020
Assigned To Examiner
Dec 19, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Dec 19, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 6, 2019
New Application Office Supplied Data Entered
Oct 5, 2019
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24